| No. of patients |
---|---|
Age, years | |
 Median (range) | 73.5 (26–85) |
  ≥ 65 | 46 (85.2%) |
  < 65 | 8 (14.8%) |
KPS | |
 Median (range) | 60 (30–100) |
  ≥ 70 | 15 (27.8%) |
  < 70 | 39 (72.2%) |
Gender | |
 Male | 25 (46.3%) |
 Female | 29 (53.7%) |
Cognitive impairment at diagnosis of relapse a | |
 Yes | 30 (55.6%) |
 No | 24 (44.4%) |
Hemiparesis at diagnosis of relapse | |
 Yes | 12 (22.2%) |
 No | 42 (77.8%) |
Seizures at diagnosis of relapse | |
 Yes | 8 (14.8%) |
 No | 46 (85.2%) |
Steroid use at diagnosis of relapse | |
 Yes | 28 (51.9%), median dose 12 mg (range 2–24 mg) |
 No | 26 (48.1%) |
Involvement of DBS | |
 Yes | 38 (70.4%) |
 No | 16 (29.6%) |
Distribution of lesions in cMRI | |
 Unifocal | 22 (40.7%) |
 Multifocal | 30 (55.6%) |
 Diffuse leptomeningeal | 2 (3.7%) |
CSF cytology | |
 Positive | 4 (7.4%) |
 Negative | 13 (24.1%) |
 Not done | 37 (68.5%) |
Charlson Comorbidity Index | |
 Score 0 | 35 (64.8%) |
 Score ≥ 1 | 19 (35.2%) |
Status before salvage treatment | |
 Relapse | 31 (57.4%) |
 Refractory | 23 (42.6%) |
Relapse/progression occurred in | |
 2006–2009 | 13 (24.1%) |
 2010–2015 | 22 (40.7%) |
 2016–2022 | 19 (35.2%) |